Notice: This company has been marked as potentially delisted and may not be actively trading. CinCor Pharma (CINC) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period CinRx Pharma portfolio company CinDome raises $40M toward Series B roundMay 28, 2024 | bizjournals.comDelveInsight Business Research, LLP: Global Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsightApril 26, 2024 | finanznachrichten.deGlobal Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsightApril 26, 2024 | tmcnet.comCinCor Pharma Inc.March 22, 2024 | thestreet.comPurdue Pharma to plead guilty in $8bn opioid settlementDecember 12, 2023 | bbc.comImpel Pharmaceuticals hit by another C-suite departureDecember 6, 2023 | bizjournals.comCatalyst Pharma's Finance Chief to Retire, Be Succeeded by Impel's CFODecember 4, 2023 | marketwatch.comSmall Pharma Inc. (DMT.V)November 4, 2023 | ca.finance.yahoo.comAbivax Readies $250 Million U.S. IPO For Drug PipelineOctober 20, 2023 | msn.comDiabetic Kidney Disease Global Market Report 2023June 9, 2023 | uk.finance.yahoo.com8-K: IMPEL PHARMACEUTICALS INCMay 11, 2023 | marketwatch.comChronic Kidney Disease Pipeline Booms as 90+ Therapies Likely to Enter in the Treatment Domain | DelveInsightMay 9, 2023 | finance.yahoo.comFinancial Results for the Year Ended 31 December -3-April 25, 2023 | finanznachrichten.deCinCor Pharma, Inc. (NASDAQ:CINC) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of CinCor Pharma, Inc. (NASDAQ:CINC - Get Rating) have received an average recommendation of "Hold" from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and two have issued a buyMarch 20, 2023 | marketbeat.comNASDAQ Biotechnology IndexMarch 16, 2023 | reuters.comHOOKIPA Pharma Appoints Terry Coelho to its Board of DirectorsMarch 13, 2023 | finance.yahoo.comBoothbay Fund Management LLC Purchases Shares of 13,718 CinCor Pharma, Inc. (NASDAQ:CINC)Boothbay Fund Management LLC purchased a new stake in CinCor Pharma, Inc. (NASDAQ:CINC - Get Rating) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 13,718 shares of the company's stock, valued at approximately $450,000. A numbeMarch 2, 2023 | marketbeat.comTrading was temporarily halted for "CINC" at 07:02 PM with a stated reason of "News pending."February 24, 2023 | marketbeat.comCinCor Pharma, Inc. (NASDAQ:CINC) Given Average Recommendation of "Moderate Buy" by AnalystsCinCor Pharma, Inc. (NASDAQ:CINC - Get Rating) has been given a consensus rating of "Hold" by the six analysts that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the companFebruary 23, 2023 | marketbeat.comCinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of BaxdrostatFebruary 21, 2023 | finance.yahoo.comState Board of Administration of Florida Retirement System Invests $230,000 in CinCor Pharma, Inc. (NASDAQ:CINC)State Board of Administration of Florida Retirement System purchased a new position in CinCor Pharma, Inc. (NASDAQ:CINC - Get Rating) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 7,000 shares of the company's stoFebruary 15, 2023 | marketbeat.comThere's a Lot to Love About Mineralys' Valentine's Day IPO (CINC)MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 millionFebruary 13, 2023 | marketbeat.comCinCor Pharma, Inc. (NASDAQ:CINC) Short Interest Down 74.7% in JanuaryCinCor Pharma, Inc. (NASDAQ:CINC - Get Rating) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 338,600 shares, a decline of 74.7% from the January 15th total of 1,340,000 shares. Approximately 2.0% of the company's stock are short sold. Based on an average trading volume of 577,600 shares, the days-to-cover ratio is currently 0.6 days.February 10, 2023 | marketbeat.comAs demand for Covid vaccines falls, AstraZeneca lines up 'blockbuster' products for 2023February 9, 2023 | msn.comThese 2 Healthcare Stocks Have Doubled in 2023 (CINC)Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks.February 1, 2023 | marketbeat.comCinCor Pharma, Inc. (NASDAQ:CINC) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of CinCor Pharma, Inc. (NASDAQ:CINC - Get Rating) have received an average rating of "Moderate Buy" from the eight analysts that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have givenJanuary 29, 2023 | marketbeat.comCinCor Pharma, Inc. (NASDAQ:CINC) Short Interest Down 38.2% in JanuaryCinCor Pharma, Inc. (NASDAQ:CINC - Get Rating) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 1,340,000 shares, a drop of 38.2% from the December 31st total of 2,170,000 shares. Based on an average daily volume of 591,500 shares, the days-to-cover ratio is presently 2.3 days. Approximately 7.7% of the company's shares are short sold.January 27, 2023 | marketbeat.comADRs End Higher; AstraZeneca, Barclays Trade ActivelyJanuary 24, 2023 | marketwatch.comBritain's AstraZeneca launches tender offer for CinCor PharmaJanuary 23, 2023 | msn.comAstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.January 23, 2023 | finance.yahoo.comCambridge Investment Research Advisors Inc. Invests $204,000 in CinCor Pharma, Inc. (NASDAQ:CINC)Cambridge Investment Research Advisors Inc. bought a new position in shares of CinCor Pharma, Inc. (NASDAQ:CINC - Get Rating) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 6,225 shares of the company's stock, valued at approximately $204,00January 16, 2023 | marketbeat.comWill 2023 be the year that pharma M&A makes a comeback?January 12, 2023 | msn.comCinCor Pharma (NASDAQ:CINC) Lowered to Equal Weight at BarclaysBarclays downgraded shares of CinCor Pharma from an "overweight" rating to an "equal weight" rating in a research note on Thursday.January 12, 2023 | marketbeat.comAstraZeneca Is Acquiring CinCor Pharma: Market Values Interesting CVR At $3.21January 12, 2023 | seekingalpha.comAstraZeneca reaches deal to buy CinCor Pharma for up to $1.8 billionJanuary 11, 2023 | bizjournals.comAstraZeneca Stock Nabs Brief Breakout After $1.8 Billion CinCor BuyoutJanuary 10, 2023 | finance.yahoo.comEQUITY ALERT: The M&A Class Action Firm Announces the Investigation of CinCor Pharma, Inc - CINCJanuary 10, 2023 | marketwatch.comAstraZeneca Stock Nabs Breakout After $1.8 Billion CinCor BuyoutJanuary 10, 2023 | finance.yahoo.comCinCor Pharma Target of Unusually High Options Trading (NASDAQ:CINC)CinCor Pharma, Inc. (NASDAQ:CINC - Get Rating) saw some unusual options trading on Tuesday. Stock investors purchased 5,139 put options on the stock. This represents an increase of 922% compared to the typical daily volume of 503 put options.January 10, 2023 | marketbeat.comAstraZeneca buying hypertension-focused CinCor for up to $1.8 billionJanuary 9, 2023 | msn.comAstraZeneca to Buy CinCor Pharma for Up to $1.8 BillionJanuary 9, 2023 | finance.yahoo.comAstraZeneca reaches deal to buy CinCor Pharma for up to $1.8BJanuary 9, 2023 | finance.yahoo.comAstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion DealJanuary 9, 2023 | finance.yahoo.comBiotechs CinCor, Albireo Jump on Takeovers by Larger DrugmakersJanuary 9, 2023 | finance.yahoo.comAstraZeneca agrees to buy U.S.-based CinCor in deal valued at $1.3 billionJanuary 9, 2023 | msn.comAstraZeneca to buy CinCor Pharma for up to $1.8bnJanuary 9, 2023 | thetimes.co.ukAstraZeneca to Buy CinCor Pharma for Around $1.3 billionJanuary 9, 2023 | wsj.comAstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln dealJanuary 9, 2023 | reuters.comThese Stocks Are Moving the Most Monday: CinCor Pharma, Macy’s, Alibaba, and MoreJanuary 9, 2023 | barrons.comAstraZeneca To Acquire CinCor Pharma To Strengthen Cardiorenal PipelineJanuary 9, 2023 | markets.businessinsider.com Get CinCor Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CINC and its competitors with MarketBeat's FREE daily newsletter. Email Address Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles." And if you’d like to get your hands on this, here you go, the complete breakdown. CINC Media Mentions By Week CINC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CINC News Sentiment▼0.300.60▲Average Medical News Sentiment CINC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CINC Articles This Week▼00▲CINC Articles Average Week Get CinCor Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CINC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRNX News Today ALKS News Today AXSM News Today RARE News Today BHVN News Today APLS News Today PBH News Today RNA News Today OGN News Today PTCT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CINC) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CinCor Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CinCor Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CINC Stock Alerts